Where PhDs and companies meet
Menu
Login

Postdoctoral Researcher in cellular reprogramming and regenerative medicine in ophthalmology

ABG-133647 Job Any
2025-10-07 Fixed-term 36 Month > €35,000 and < €45,000 annual gross
Hôpital Fondation A. de Rothschild
- Ile-de-France - France
Biotechnology
Cell reprogramming; Cell culture; scRNA-seq; ATAC-seq; Computational software.
Research and Development

Employer

The project will be carried out at the Translational Research in Experimental Corneal Surgery (TREX) laboratory at the Rothschild Foundation Hospital (Paris, France – https://www.fo-rothschild.fr/), the Saint Louis Research Institute in the “Stem Cell and Biotechnology” team (U1342 – Paris, France – https://irsl.u-paris.fr/), and the Vision Institute (Paris, France – https://www.institut-vision.org/).

Position and assignments

Isolate, amplify, characterize primary human cells (immunofluorescence, RT-qPCR, clonogenicity, scRNA-seq, ATAC-seq)
Participate in multi-omics analyses (scRNA-seq, ATAC-seq)
Establish cell reprogramming protocols
Functional evaluation of reprogrammed cells in vitro and in vivo
Co-supervision of Master's 2 students
Contribute to scientific publications, patent filings, and oral presentations
Participate in project meetings and team dynamics

Geographic mobility:

No business trip

Telework

Occasionnal

Profile

PhD in cell biology / biotechnology

Solid experience in cell culture (primary cells, differentiation, transduction / transfection, possibly iPSCs)

Good knowledge of molecular biology, histology, and microscopy

Knowledge and experience in scRNA-seq, ATAC-seq, and bioinformatics analysis are a plus

Ability to work independently while interacting in a multidisciplinary team. Scientific rigor, motivation, creativity, initiative, and a desire to develop projects. Good communication and organizational skills.

Scientific English essential; French is not mandatory

A minimum of one publication as first author required

Goals

The Recor project lies at the crossroads of cell biology and computer science, aiming to open up a new avenue for the manufacture of cell therapy products. The project aims to develop a treatment for limbal stem cell deficiency (LSCD) by generating corneal epithelial stem cells from adult somatic cells by direct cellular reprogramming. With our partner, we will integrate multi-omics data (scRNA-seq, ATAC-seq) using bioinformatics tools to define optimal reprogramming conditions, then confirm them through phenotypic characterization and in-vivo functional validation. This regenerative medicine program, funded by the French National Research Agency (ANR) and conducted in international collaboration, is designed to provide the preclinical evidence necessary for clinical translation in humans.

Partager via
Apply
Close

Vous avez déjà un compte ?

Nouvel utilisateur ?